Advertisement

Topics

Myovant's Drug To Treat Uterine Fibroids Hits Key Goals In Phase III Study

08:03 EDT 14 May 2019 | RTTNews

Myovant Sciences' (MYOV) phase III study of once daily Relugolix combination therapy met its primary and key secondary goals in women with uterine fibroids and heavy menstrual bleeding.

Original Article: Myovant's Drug To Treat Uterine Fibroids Hits Key Goals In Phase III Study

NEXT ARTICLE

More From BioPortfolio on "Myovant's Drug To Treat Uterine Fibroids Hits Key Goals In Phase III Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...